ZLDPF Zealand Pharma A/S

REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025

REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025

Press release – No. 17 / 2025

REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025

Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism.

Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET)

Venue: Goldman Sachs International, Plumtree Court, 2 Stonecutter Street, London EC4A 4AU

Register for in-person or virtual attendance:

A replay of the webcast will be archived on the company’s website following the presentation.

Zealand Pharma speakers:

  • Adam Steensberg, Chief Executive Officer
  • Henriette Wennicke, Chief Financial Officer
  • David Kendall, Chief Medical Officer
  • Eric Cox, Chief Commercial Officer
  • Utpal Singh, Chief Scientific Officer

External experts:

  • Dr. Carel Le Roux, MBChB, MSC, FRCP, FRCPath, PhD, Professor of Experimental Pathology at University College Dublin
  • Jonathan Roth, PhD, Metabolic researcher and pioneer in amylin-leptin biology
  • Louis J. Aronne, MD, FACP, DABOM, Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Email:

Neshat Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email:

Rachel James-Owens (Media)

Vice President, Corporate Communications and Media Relations

Zealand Pharma

Amber Fennell, Jessica Hodgson, Sean Leous (Media)

ICR Healthcare



+44 (0) 7739 658 783



EN
01/12/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Wim Lewi
FAGR FAGRON SA
ZLDPF ZEALAND PHARMA A/S
EKOP EKOPAK NV
12h / 31m 12h / 31m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Model update, multiple important catalysts ahead

We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...

ZLDPF ZEALAND PHARMA A/S
12h / 59m 12h / 59m 1 EN
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Wim Lewi
ZLDPF ZEALAND PHARMA A/S
SHUR SHURGARD SELF STORAGE LIMITED
01/09/26 January 9, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...

Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.

ZLDPF ZEALAND PHARMA A/S
01/09/26 January 9, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomput...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch